Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Consumer Leadership

Help Wanted: FDA Begins Search for New CDER Director

This article was originally published in RPM Report

  • Analysis

Executive Summary

FDA has a lot of hard work ahead to make the new drug safety law a reality. Its first task: find a new director for the Center for Drug Evaluation & Research. That decision might be the most important one the agency makes in determining how the new law works.
Table

View full table

Advertisement

Related Content

Pink Sheet
Translating Obama For FDA
Pink Sheet
The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability
Pink Sheet
FDA Insider: Agency Looks Carefully Inside for New CDER Head
Pink Sheet
Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
Pink Sheet
FDA Amendments Act: More Regulation = More Comfort and More Products
In Vivo
Avandia and the Commercial Impact of FDA's Credibility Gap
Pink Sheet
The Politics of Drug Safety: An FDA Whistleblower's Push for Reform
Pink Sheet
FDA's Selective Response to the IoM Drug Safety Report
Pink Sheet
FDA Leadership Changes Reflect Budgetary, Scientific Challenges
Pink Sheet
Everything but the Kitchen Sink: IoM Drug Safety Report Gives FDA Options

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical Consumer Leadership
UsernamePublicRestriction

Register

PS080344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By